1.
|
17 p, 1.2 MB |
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
/
Munir, Talha (St James's Hospital) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Benjamini, Ohad (Sheba Medical Center) ;
Janssens, Ann (UZ Leuven Gasthuisberg) ;
Levin, Mark-David (Albert Schweitzer Hospital) ;
Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ;
Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ;
Stevens, Don (Norton Cancer Institute) ;
Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ;
Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ;
Yagci, Munci (Gazi Universitesi Tip Fakultesi) ;
Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ;
Qi, Keqin (Janssen Research & Development) ;
Qi, Qianya (Janssen Research & Development) ;
Parisi, Lori (Janssen Research & Development) ;
Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ;
Schuier, Natasha (Janssen Research & Development) ;
Baeten, Kurt (Janssen Research & Development) ;
Howes, Angela (Janssen Research & Development) ;
Caces, Donne Bennett (Janssen Research & Development) ;
Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ;
Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699
|
|
2.
|
16 p, 3.5 MB |
Biomarkers Found in the Tumor Interstitial Fluid may Help Explain the Differential Behavior Among Keratinocyte Carcinomas
/
Matas-Nadal, Clara (Hospital de Santa Caterina (Salt, Girona)) ;
Bech-Serra, Joan-Josep (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gatius, Sònia (Hospital Universitari Arnau de Vilanova) ;
Gomez, Xavier (Universitat de Lleida. Departament de Ciències Mèdiques Bàsiques) ;
Ribes-Santolaria, Marina (Universitat de Lleida. Departament de Ciències Mèdiques Bàsiques) ;
Guasch-Vallés, Marta (Universitat de Lleida. Departament de Ciències Mèdiques Bàsiques) ;
Pedraza, Neus (Universitat de Lleida. Departament de Ciències Mèdiques Bàsiques) ;
Casanova, Josep M. (Hospital Universitari Arnau de Vilanova) ;
De La Torre Gómez, Gisela Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gari, Eloi (Universitat de Lleida. Departament de Ciències Mèdiques Bàsiques) ;
Aguayo-Ortiz, Rafael S. (Hospital Universitari Arnau de Vilanova)
Basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (SCCs) are the most frequent types of cancer, and both originate from the keratinocyte transformation, giving rise to the group of tumors called keratinocyte carcinomas (KCs). [...]
2023 - 10.1016/j.mcpro.2023.100547
Molecular and Cellular Proteomics, Vol. 22 Núm. 6 (june 2023) , p. 100547
|
|
3.
|
|
4.
|
|
5.
|
29 p, 5.2 MB |
Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression
/
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ortega-Sabater, C. (Mathematical Oncology Laboratory. Department of Mathematics & amp; Institute of Applied Mathematics in Science and Engineering. Universidad de Castilla-La Mancha) ;
Thampi, Namitha (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández Fuentes, Narcís (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guerrero Murillo, Mercedes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez Moreno, Alba (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vinyoles, Meritxell (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Campos, Diana (DiNA Science. S.A) ;
Giménez, Carles (DiNA Science. S.A) ;
Boer, Judith M. (Princess Maxima Center for Pediatric Oncology) ;
den Boer, Monique L. (Department of Pediatric Oncology and Hematology. Erasmus Medical Center - Sophia Children's Hospital) ;
Calvo, Gabriel F. (Mathematical Oncology Laboratory. Department of Mathematics & amp; Institute of Applied Mathematics in Science and Engineering. Universidad de Castilla-La Mancha) ;
Camós, Mireia (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Fuster, José Luis (Pediatric Hematology and Oncology Department. Hospital Clínico Universitario Virgen de la Arrixaca. Instituto Murciano de Investigación Biosanitaria (IMIB)) ;
Velasco, P. (Hospital Universitari Vall d'Hebron) ;
Ballerini, Paola (AP-HP. Service of Pediatric Hematology. Hopital Armand Trousseau) ;
Locatelli, Franco (Bambino Gesù Children's Hospital. Catholic University of Sacred Heart) ;
Mullighan, Charles G. (Department of Pathology. St. Jude Children's Research Hospital) ;
Spierings, Diana C.J. (European Research Institute for the Biology of Aging (ERIBA). University of Groningen. University Medical Center Groningen) ;
Foijer, Floris (European Research Institute for the Biology of Aging (ERIBA). University of Groningen. University Medical Center Groningen) ;
Pérez-García, Víctor M. (Mathematical Oncology Laboratory. Department of Mathematics & amp; Institute of Applied Mathematics in Science and Engineering. Universidad de Castilla-La Mancha) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Chromosomal instability (CIN) lies at the core of cancer development leading to aneuploidy, chromosomal copy-number heterogeneity (chr-CNH) and ultimately, unfavorable clinical outcomes. Despite its ubiquity in cancer, the presence of CIN in childhood B-cell acute lymphoblastic leukemia (cB-ALL), the most frequent pediatric cancer showing high frequencies of aneuploidy, remains unknown. [...]
2024 - 10.1038/s44321-023-00006-w
EMBO Molecular Medicine, Vol. 16 Núm. 1 (16 2024) , p. 64-92
|
|
6.
|
7 p, 784.4 KB |
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma : A GELTAMO Trial
/
Cabrero, Monica (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
Martín García-Sancho, Alejandro (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Gayoso, Jorge (Hospital General Universitario Gregorio Marañón) ;
Jarque, Isidro (Hospital Universitari i Politècnic La Fe (València)) ;
López, Javier (Hospital Universitario Ramón y Cajal (Madrid)) ;
Grande García, Carlos (Hospital 12 de Octubre (Madrid)) ;
Heras, Inmaculada (Hospital Morales Messeguer) ;
Arranz, Reyes (Hospital Universitario de la Princesa (Madrid)) ;
Bernal, Teresa (Hospital Universitario Central de Asturias) ;
Perez-Lopez, Estefenia (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
López-Godino, Oriana (Hospital Morales Messeguer) ;
Conde, Eulogio (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Caballero, Dolores (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
Universitat Autònoma de Barcelona
We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). [...]
2017 - 10.1016/j.bbmt.2016.10.003
Biology of blood and marrow transplantation, Vol. 23 Núm. 1 (january 2017) , p. 53-59
|
|
7.
|
12 p, 2.5 MB |
Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice
/
Galindo Campos, Miguel A. (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Lutfi, Nura (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Bonnin, Sarah (Centre de Regulació Genòmica) ;
Martínez Cáceres, Carlos (Instituto Murciano de Investigación Biosanitaria-Laboratorio de Investigación Biosanitaria-Arrixaca) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Hernández, Violeta (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Martín Caballero, Juan (Instituto Cajal. Consejo Superior de Investigaciones Científicas (CSIC)) ;
Ampurdanés, Coral (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Gimeno, Ramón (Laboratory of Immunology. Department of Pathology) ;
Colomo, Lluís (Hospital del Mar (Barcelona, Catalunya)) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guilbaud, Guillaume (Division of Protein and Nucleic Acid Chemistry. Medical Research Council Laboratory of Molecular Biology) ;
Dantzer, Françoise (Biotechnology and Cell Signaling. Unité Mixte de Recherche (UMR) 7242 Centre National de la Recherche Scientifique. Laboratory of Excellence Medalis. École Supérieure de Biotechnologie de Strasbourg. Strasbourg University) ;
Navarro, Pilar (Hospital del Mar Medical Research Institute. Unidad Asociada IIBB-CSIC) ;
Murga, Matilde (Genomic Instability Group. Spanish National Cancer Research Centre) ;
Fernández Capetillo, Oscar (Science for Life Laboratory. Department of Medical Biochemistry and Biophysics. Karolinska Institutet) ;
Bigas Salvans, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sale, Julian E. (Division of Protein and Nucleic Acid Chemistry. Medical Research Council Laboratory of Molecular Biology) ;
Yélamos, José (Laboratory of Immunology. Department of Pathology)
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. [...]
2022 - 10.1182/blood.2021012805
Blood, Vol. 139 Núm. 2 (13 2022) , p. 228-239
|
|
8.
|
12 p, 5.4 MB |
Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept
/
Pernin, Vincent (University Hospital of Montpellier (França)) ;
Meneghini, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Torija Recasens, Alba (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jouve, Thomas (Grenoble University Hospital) ;
Del Bello, Arnaud (Universidad de Valladolid) ;
Sanz-Muñoz, Iván (Universidad de Valladolid) ;
Eiros, Jose Maria (Universidad de Valladolid) ;
Donadeu, Laura (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Puig-Polo, Carol (Hospital Universitari de Bellvitge) ;
Morandeira Rego, Francisco (Hospital Universitari de Bellvitge) ;
Navarro Velázquez, Sergio (Hospital Universitari de Bellvitge) ;
Masuet-Aumatell, Cristina (Hospital Universitari de Bellvitge) ;
Favà, Alexandre (Hospital Universitari de Bellvitge) ;
LeQuintrec, Moglie (University Hospital of Montpellier (França)) ;
Kamar, Nassim (Grenoble University Hospital) ;
Crespo, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bestard, Oriol (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Emerging data suggest that costimulation blockade with belatacept effectively controls humoral alloimmune responses. However, whether this effect may be deleterious for protective anti-infectious immunity remains poorly understood. [...]
2022 - 10.3389/fimmu.2022.918887
Frontiers in immunology, Vol. 13 (july 2022)
|
|
9.
|
12 p, 843.6 KB |
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy
/
Zhang, Xuanye (Sun Yat-sen University Cancer Center) ;
Tian, Dan (Guangdong Academy of Medical Sciences) ;
Chen, Yue (The Eighth Affiliated Hospital of Sun Yat-sen University) ;
Chen, Chen (Sun Yat-sen University Cancer Center) ;
He, Li-Na (Sun Yat-sen University Cancer Center) ;
Zhou, Yixin (Sun Yat-sen University Cancer Center) ;
Li, Haifeng (Sun Yat-sen University Cancer Center) ;
Lin, Zuan (Sun Yat-sen University Cancer Center) ;
Chen, Tao (Sun Yat-sen University Cancer Center) ;
Wang, Yuhong (Sun Yat-sen University Cancer Center) ;
Russo, Alessandro (A.O. Papardo) ;
Nadal, Ernest (Hospital Universitari de Bellvitge) ;
Passiglia, Francesco (S. Luigi Gonzaga Hospital) ;
Soo, Ross Andrew (National University Health System) ;
Watanabe, Satoshi (Niigata University Graduate School of Medical and Dental Sciences) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Oh, In-Jae (Hwasun Hospital) ;
Fu, Sha (Sun Yat-sen University) ;
Hong, Shaodong (Sun Yat-sen University Cancer Center) ;
Zhang, Li (Sun Yat-sen University Cancer Center) ;
Universitat Autònoma de Barcelona
The aim of this study was to evaluate the safety and survival outcomes of anti-programmed cell death (PD)-1/programmed cell death-ligand 1 (PD-L1) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) and different hepatitis B virus (HBV) infection status. [...]
2021 - 10.21037/tlcr-21-455
Translational Lung Cancer Research, Vol. 10 (july 2021) , p. 3191-3202
|
|
10.
|
9 p, 4.2 MB |
MiR-125b downregulates macrophage scavenger receptor type B1 and reverse cholesterol transport
/
Hueso, Miguel (Institut d'Investigació Biomèdica de Bellvitge) ;
Griñán, Raquel (Institut d'Investigació Biomèdica Sant Pau) ;
Mallen, Adrián (Institut d'Investigació Biomèdica de Bellvitge) ;
Navarro, Estanislao (Institut d'Investigació Biomèdica de Bellvitge) ;
Purqueras, Elvira (Institut d'Investigació Biomèdica de Bellvitge) ;
Gomá, Montse (Institut d'Investigació Biomèdica de Bellvitge) ;
Sbraga, Fabritzio (Institut d'Investigació Biomèdica de Bellvitge) ;
Blasco-Lucas, Arnau (Hospital Universitari de Bellvitge) ;
Revilla, Giovanna (Institut d'Investigació Biomèdica Sant Pau) ;
Santos, David (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Canyelles, Marina (Institut d'Investigació Biomèdica Sant Pau) ;
Julve i Gil, Josep (Institut d'Investigació Biomèdica Sant Pau) ;
Escolà-Gil, Joan Carles (Institut d'Investigació Biomèdica Sant Pau) ;
Rotllan, Noemi (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Objective: To determine whether miR-125b regulates cholesterol efflux in vivo and in vitro through the regulation of scavenger receptor type B1 (SR-B1). Approach and results: We demonstrated that miR-125b is up-regulated in the human aortas of patients with CAD and is located in macrophages and vascular smooth muscle cells (VSMCs). [...]
2022 - 10.1016/j.biopha.2021.112596
Biomedicine & pharmacotherapy, Vol. 146 (february 2022) , p. 112596
|
|